Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2019 Sep;181(3):609-611.
doi: 10.1111/bjd.17822. Epub 2019 May 12.

Open-label, investigator-initiated, single-site exploratory trial evaluating secukinumab, an anti-interleukin-17A monoclonal antibody, for patients with moderate-to-severe hidradenitis suppurativa

L Prussick  1 , B Rothstein  1 , D Joshipura  1 , A Saraiya  2 , Y Turkowski  3 , R Abdat  1 , A Alomran  1 , P Zancanaro  1 , C Kachuk  1 , N Dumont  1 , A B Gottlieb  4 , D Rosmarin  1
Affiliations
Clinical Trial

Open-label, investigator-initiated, single-site exploratory trial evaluating secukinumab, an anti-interleukin-17A monoclonal antibody, for patients with moderate-to-severe hidradenitis suppurativa

L Prussick et al. Br J Dermatol. 2019 Sep.
No abstract available

PubMed Disclaimer

References

    1. Jemec GBE. Clinical practice: hidradenitis suppurativa. New Engl J Med 2012; 366:158-64.
    1. Matusiak L, Szczęch J, Bieniek A, Nowicka-Suszko D et al. Increased interleukin (IL)-17 serum levels in patients with hidradenitis suppurativa: implications for treatment with anti-IL-17 agents. J Am Acad Dermatol 2017; 76:670-5.
    1. Kimball AB, Okun M, Williams D et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med 2016; 375:422-34.